Wai Chun Bio-Technology Limited (Stock Code: 660) announced its unaudited interim results for the six months ended 31 December 2025. The group recorded revenue of HK$352.15 million, marking an increase from HK$161.06 million in the corresponding period of 2024. Gross profit rose to HK$35.66 million from HK$21.13 million. The gross profit margin stood at about 10.1%.

According to the announcement, loss attributable to owners of the company was HK$5.94 million, a decrease compared to the HK$13.66 million loss in the same period of 2024. The company highlighted that higher market consumption and demand contributed to revenue growth, while reduced finance costs also helped lower the overall loss. Selling expenses rose in line with increased sales activities, and administrative expenses increased partly due to higher staff costs.

The announcement stated that as of 31 December 2025, the group had net current liabilities of HK$61.19 million and total debts of HK$141.90 million, supported by funding measures from its ultimate holding company. The board resolved not to recommend an interim dividend for the reporting period. The company indicated that it would continue exploring potential strategic acquisitions to strengthen its earnings base and improve overall financial health.